Sam Brusco, Associate Editor09.20.22
Stryker has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its OptaBlate bone tumor ablation system.
Adding OptaBlate to Stryker’s Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation to treat metastatic vertebral body fractures.
"Stryker's new bone tumor ablation (BTA) system is a significant improvement on existing technology and builds on Stryker's IVS portfolio," Dr. Anthony Brown, a Vascular and Interventional Radiologist at Radiology Imaging Associates, Colo., told the press. "There is no more deserving patient population for our attention and intervention; OptaBlate will change lives."
OptaBlate is Stryker’s first interventional oncology technology. It features four probes and Stryker’s patented microinfusion technology so physicians can customize their procedure.
The system treats two vertebral body levels at once via a bipedicular approach. According to Stryker data, it can reduce ablation time by three minutes. Its microinfusion tech keeps the zone hydrated to reduce impedance errors and prevent charring.
"Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs," said Greg Siller, VP and GM, Interventional Spine business, Stryker. "OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning."
Stryker will showcase OptaBlate at this year’s North American Spine Society (NASS) annual meeting.
Adding OptaBlate to Stryker’s Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation to treat metastatic vertebral body fractures.
"Stryker's new bone tumor ablation (BTA) system is a significant improvement on existing technology and builds on Stryker's IVS portfolio," Dr. Anthony Brown, a Vascular and Interventional Radiologist at Radiology Imaging Associates, Colo., told the press. "There is no more deserving patient population for our attention and intervention; OptaBlate will change lives."
OptaBlate is Stryker’s first interventional oncology technology. It features four probes and Stryker’s patented microinfusion technology so physicians can customize their procedure.
The system treats two vertebral body levels at once via a bipedicular approach. According to Stryker data, it can reduce ablation time by three minutes. Its microinfusion tech keeps the zone hydrated to reduce impedance errors and prevent charring.
"Our commitment to our customers and understanding their needs has never been stronger. The collaboration has helped us to develop a more efficient bone tumor ablation system to address their unmet needs," said Greg Siller, VP and GM, Interventional Spine business, Stryker. "OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer, and this is just the beginning."
Stryker will showcase OptaBlate at this year’s North American Spine Society (NASS) annual meeting.